The systemic lupus erythematosus (SLE) is a severe, complex autoimmune disorder, characterised by a loss of self-tolerance and the generation of autoimmune antibodies against the nuclear and cytoplasmic antigens. Immune complexes accumulate in numerous organs, causing inflammation and organ damage via complement activation and immune-mediated injury. SLE pathogenesis is complex; it involves hormonal factors, genetic predisposition, epigenetic regulation, and environmental factors like UV radiation and infectious diseases. Autoimmune disease is maintained by dysregulated cytokine signalling, aberrant B and T cell activation, and insufficient clearance of apoptotic debris. Systemic lupus erythematosus (SLE) can manifest clinically with a diverse array of symptoms, ranging from musculoskeletal involvement and constitutional symptoms to severe organ-specific complications such as lupus nephritis, neuropsychiatric disorders, and cardiovascular or pulmonary manifestations. The disease’s severity differs among individuals. Advancements in molecular immunology have enhanced our understanding of the mechanisms that drive infectious diseases, paving the way for novel customised therapies aimed at reducing toxicity while achieving remission. A comprehensive understanding of the immunopathogenic pathways is crucial for enhancing the diagnosis, prognosis, and precision-based treatment of SLE.